Establishment Labs Announces Participation in the Jefferies Virtual Healthcare Conference
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a company specializing in women's health, will feature CEO Juan José Chacón-Quirós and CFO Renee Gaeta at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. Their presentation is scheduled for June 4 at 2:00 pm ET. A live webcast will be accessible on the Establishment Labs investor relations website, with an archived version available later. The company designs and manufactures silicone gel-filled breast implants under the Motiva Implants® brand, complying with FDA and ISO standards, and has a presence in over 80 countries.
- Participation in Jefferies Virtual Healthcare Conference showcases company leadership.
- Motiva Implants® are available in over 80 countries, indicating strong market presence.
- Compliance with FDA and ISO standards highlights product quality and safety.
- None.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the Jefferies Virtual Healthcare Conference, which is being held June 1-4, 2021. Mr. Chacón-Quirós and Mrs. Gaeta are scheduled to speak to conference attendees at 2:00 pm ET on Friday, June 4, 2021.
A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.
About Establishment Labs
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005075/en/
FAQ
When is Establishment Labs participating in the Jefferies Virtual Healthcare Conference?
Who from Establishment Labs will speak at the Jefferies Conference?
Where can I watch the webcast of Establishment Labs' presentation?
What products does Establishment Labs focus on?
In how many countries are Motiva Implants® available?
